Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WIN-Partners CoTSE:3183 -0.46%67 ROC (Joel Greenblatt) % is 51.47% as of Mar. 2026, which is 16% below its 10-year median of 60.96. GuruFocus rates TSE:3183 with a GF Score™ of 67/100 and a GF Value™ of 円1,529.64 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 120 Medical Distribution companies, WIN-Partners Co ranks better than 89.17% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. WIN-Partners Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 51.47%.
The historical rank and industry rank for WIN-Partners Co's ROC (Joel Greenblatt) % or its related term are showing as below:
TSE:3183'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 50.89 Med: 60.96 Max: 108.51
Current: 51.16
During the past 13 years, WIN-Partners Co's highest ROC (Joel Greenblatt) % was 108.51%. The lowest was 50.89%. And the median was 60.96%.
TSE:3183's ROC (Joel Greenblatt) % is ranked better than 89.17% of 120
companies
in the Medical Distribution industry
Industry Median: 15.045
vs TSE:3183: 51.16
WIN-Partners Co's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -3.60% per year.
WIN-Partners Co (TSE:3183) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
WIN-Partners Co ROC (Joel Greenblatt) % Related Terms
WIN-Partners Co ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for WIN-Partners Co's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:3183 vs MCK, COR, CAH: ROC (Joel Greenblatt) % Comparison
For the Medical Distribution subindustry, WIN-Partners Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WIN-Partners Co ROC (Joel Greenblatt) % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, WIN-Partners Co's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where WIN-Partners Co's ROC (Joel Greenblatt) % falls into.
WIN-Partners Co ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 51.47% mean?
WIN-Partners Co (TSE:3183) has a ROC (Joel Greenblatt) % of 51.47% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on WIN-Partners Co and its competitors. This is 16% below median its historical median of 60.96. Over the past decade, WIN-Partners Co's ROC (Joel Greenblatt) % has ranged from 50.89 to 108.51. According to the industry distribution chart, WIN-Partners Co ranks #13 out of 120 companies in the Medical Distribution industry, placing it in the top 10.8%.
Is WIN-Partners Co's ROC (Joel Greenblatt) % too high?
WIN-Partners Co's current ROC (Joel Greenblatt) % of 51.47% is 16% below median its 10-year median of 60.96. Over the past 10 years, this metric has ranged from a low of 50.89 to a high of 108.51. The Medical Distribution industry median ROC (Joel Greenblatt) % is 15.05. WIN-Partners Co's value of 51.47% is 242.1% above this industry median. Based on the distribution chart, WIN-Partners Co ranks #13 out of 120 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, WIN-Partners Co has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WIN-Partners Co's ROC (Joel Greenblatt) % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, WIN-Partners Co ranks #13 out of 120 companies for ROC (Joel Greenblatt) %. This places WIN-Partners Co in the top 11% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 15.05. WIN-Partners Co's value of 51.47% is 242.1% above this benchmark. Historically, WIN-Partners Co's own ROC (Joel Greenblatt) % has ranged from 50.89 to 108.51 over the past decade. While the company's 10-year median is 60.96 vs. the industry median of 15.05, WIN-Partners Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Distribution company?
The median ROC (Joel Greenblatt) % among Medical Distribution companies is 15.05, based on 120 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WIN-Partners Co's current ROC (Joel Greenblatt) % of 51.47% is 242.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on WIN-Partners Co and its competitors. For the Medical Distribution industry, the median ROC (Joel Greenblatt) % is 15.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WIN-Partners Co's current ROC (Joel Greenblatt) % is 51.47%, which is 16% below median its own 10-year median of 60.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WIN-Partners Co stock overvalued right now?
Based on GuruFocus' analysis, WIN-Partners Co (TSE:3183) is currently considered Modestly Undervalued. The stock's GF Value™ is 円1,529.64, compared to a current price of 円1,308.00 — trading 14.5% below its estimated fair value. The current ROC (Joel Greenblatt) % is 51.47%, which is 16% below median its 10-year median of 60.96 and 242.1% above the Medical Distribution industry median of 15.05. WIN-Partners Co's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For WIN-Partners Co (TSE:3183), the current ROC (Joel Greenblatt) % is 51.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WIN-Partners Co (TSE:3183) Overvalued in 2026?
Based on GuruFocus' analysis, WIN-Partners Co stock appears to be undervalued.
The current stock price of 円1,308.00 is trading 14.5% below its estimated GF Value™ of 円1,529.64.
GuruFocus considers WIN-Partners Co to be Modestly Undervalued.
Key valuation signals for TSE:3183:
ROC (Joel Greenblatt) %: 51.47% (16% below median its 10-year median of 60.96)
GF Value™: 円1,529.64 vs. price of 円1,308.00 (14.5% below fair value)
Industry Position: 242.1% above the Medical Distribution median (#13 of 120)
No single metric tells the full story. See the TSE:3183 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WIN-Partners Co Ltd is engaged in the healthcare sector. The company provides medical devices to Japan's medical institutions. Its products offerings are Cardiovascular device, Insulin Pump, X-ray Angio System, Carotid Artery Stent, Stent Graft, among others. The company operates only in one segment which is the medical equipment sales business.
67GF Score
Get the complete analysis for TSE:3183
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3183 has been successfully added to your 
